Biotech | August 02, 2021
Windlas Biotech opens for subscription this week
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
The company is doubling its chemistry research capacity that should commission by Q2'FY22
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
The facility is expected to be completed in 2024
New manufacturing complex will occupy an overall footprint of approximately 2,000 square meter with six levels of manufacturing space
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
Strategic divestment of Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
PEL will explore the PLI scheme and apply if its beneficial.
Subscribe To Our Newsletter & Stay Updated
